TY - JOUR
T1 - Antibody drug conjugates
T2 - Development, characterization, and regulatory considerations
AU - Kommineni, Nagavendra
AU - Pandi, Palpandi
AU - Chella, Naveen
AU - Domb, Abraham J.
AU - Khan, Wahid
N1 - Publisher Copyright:
© 2019 John Wiley & Sons, Ltd.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Previously, cancer chemotherapy was often accompanied by severe side effects. Antibody drug conjugates (ADCs) were introduced to address this treatment complication. ADCs are a potent category of bioconjugates and immunoconjugates designed as targeted therapy for the treatment of cancer. ADCs are complex molecules composed of an antibody linked via linker chemistry to a cytotoxic payload or drug. Therefore, biologic properties of the cell-surface target antigen are important in designing an effective ADC as an anticancer agent. ADCs have the ability to discriminate between the healthy and diseased tissue, so that healthy cells are less effected and get maximum therapeutic benefit. This review describes the development, characterization, and regulatory consideration of ADCs, and it summarizes the approved products in the market and in clinical trials.
AB - Previously, cancer chemotherapy was often accompanied by severe side effects. Antibody drug conjugates (ADCs) were introduced to address this treatment complication. ADCs are a potent category of bioconjugates and immunoconjugates designed as targeted therapy for the treatment of cancer. ADCs are complex molecules composed of an antibody linked via linker chemistry to a cytotoxic payload or drug. Therefore, biologic properties of the cell-surface target antigen are important in designing an effective ADC as an anticancer agent. ADCs have the ability to discriminate between the healthy and diseased tissue, so that healthy cells are less effected and get maximum therapeutic benefit. This review describes the development, characterization, and regulatory consideration of ADCs, and it summarizes the approved products in the market and in clinical trials.
KW - antibody drug conjugates
KW - cytotoxicity
KW - monoclonal antibody
KW - synthesis
UR - http://www.scopus.com/inward/record.url?scp=85078272364&partnerID=8YFLogxK
U2 - 10.1002/pat.4789
DO - 10.1002/pat.4789
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:85078272364
SN - 1042-7147
VL - 31
SP - 1177
EP - 1193
JO - Polymers for Advanced Technologies
JF - Polymers for Advanced Technologies
IS - 6
ER -